Aytu BioPharma, Inc.

NasdaqCM:AYTU 주식 보고서

시가총액: US$14.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aytu BioPharma 관리

관리 기준 확인 2/4

Aytu BioPharma's CEO는 Josh Disbrow, Apr2015 에 임명되었습니다 의 임기는 9.17 년입니다. 총 연간 보상은 $ 708.00K, 83.3% 로 구성됩니다. 83.3% 급여 및 16.7% 보너스(회사 주식 및 옵션 포함). 는 $ 204.36K 가치에 해당하는 회사 주식의 1.29% 직접 소유합니다. 204.36K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 7.9 년입니다.

주요 정보

Josh Disbrow

최고 경영자

US$928.2k

총 보상

CEO 급여 비율63.6%
CEO 임기9.4yrs
CEO 소유권1.2%
경영진 평균 재임 기간2.7yrs
이사회 평균 재임 기간8.2yrs

최근 관리 업데이트

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Recent updates

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Feb 14
A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

CEO 보상 분석

Josh Disbrow 의 보수는 Aytu BioPharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024US$928kUS$590k

-US$16m

Mar 31 2024n/an/a

-US$14m

Dec 31 2023n/an/a

-US$18m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$17m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

보상 대 시장: Josh 의 총 보상 ($USD 928.22K )은 US 시장( $USD 677.23K ).

보상과 수익: 회사가 수익성이 없는 동안 Josh 의 보상이 증가했습니다.


CEO

Josh Disbrow (49 yo)

9.4yrs

테뉴어

US$928,217

보상

Mr. Joshua R. Disbrow, also known as Josh, serves as Chairman at Aytu Biopharma, Inc. He served as Chairman at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 until 2023 and...


리더십 팀

이름위치테뉴어보상소유권
Joshua Disbrow
Chairman & CEO9.4yrsUS$928.22k1.2%
$ 174.2k
Mark Oki
CFO, Secretary & Treasurer2.7yrsUS$584.67k0.16%
$ 23.1k
Greg Pyszczymuka
Chief Commercial Officer2.7yrsUS$516.30k0.38%
$ 55.8k
Margaret Cabano
Vice President of Operationsno data데이터 없음데이터 없음
Jarrett Disbrow
Chief Business Officer1.8yrsUS$542.10k데이터 없음
Russ McMahen
Senior Vice President of Research & Developmentno data데이터 없음데이터 없음
Ryan Selhorn
Executive Vice President of Finance & Business Optimization1.8yrs데이터 없음데이터 없음

2.7yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: AYTU 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Joshua Disbrow
Chairman & CEO8.7yrsUS$928.22k1.2%
$ 174.2k
Vivian Liu
Independent Director2.2yrsUS$77.60k0.14%
$ 20.2k
John Donofrio
Lead Independent Director8.2yrsUS$107.60k0.038%
$ 5.5k
Carl Dockery
Independent Director8.4yrsUS$72.60k0.16%
$ 23.5k
Abhinav Jain
Independent Director1.3yrsUS$79.30k0.13%
$ 19.4k

8.2yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: AYTU 의 이사회경험(평균 재직 기간 7.9 년)으로 간주됩니다.